Open access · CC-BY
via OpenAlex
Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss
Masayuki Bun, Yuichiro Ukon, Masato Ikuta, Takayuki Kitahara, Takuya Furuichi, Hiromasa Hirai, Daisuke Tateiwa, Yuya Kanie, Masayuki Furuya, Takahito Fujimori, Satoru Otsuru, Seiji Okada, Takashi Kaito
Aging Cell · 2025 · ▲ 2 citations
Abstract
Osteoporosis is characterized by reduced bone mass and structural deterioration, leading to increased fracture risk, particularly in older adults. Parathyroid hormone (PTH) is a widely used anabolic therapy for osteoporosis; however, rapid bone loss after treatment discontinuation presents a significant clinical challenge. Cellular senescence(definition) has been implicated in age-related bone fragility. However, its role in PTH-induced bone remodeling and post-treatment bone loss remains unclear. This study aimed to investigate the effects of PTH administration frequency on bone microarchitecture and cellular senescence in young and aged mice. High-frequency PTH administration improved trabecular bone volume in both age groups, but caused cortical bone thinning, increased porosity, and elevated osteoclast activity in aged mice. PTH induces senescent osteoblast-lineage-enriched cell accumulation in aged, but not young mice, accompanied by upregulation of senescence-associated markers and activation of the mechanistic Target of mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">Rapamycin(definition) Complex 1 pathway. Co-administration of the senolytic agents dasatinib and quercetin during PTH treatment reduced senescent cell burden, improved cortical porosity, and mitigated rapid bone loss after PTH discontinuation in aged mice. These findings indicate that senescent osteoblast-lineage-enriched cells contribute to bone fragility and post-treatment bone loss in aged individuals, suggesting that targeting senescence may enhance the efficacy and sustainability of PTH therapy for osteoporosis.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1111/acel.70331
- Canonical
- link ↗
- Fetched
- 2026-11-11 MST
Cite this
APA
Bun, M., Ukon, Y., Ikuta, M., Kitahara, T., Furuichi, T., Hirai, H., Tateiwa, D., Kanie, Y., Furuya, M., Fujimori, T., Otsuru, S., Okada, S., & Kaito, T. (2025). Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss. <em>Aging Cell</em>. https://doi.org/10.1111/acel.70331
Vancouver
Bun M, Ukon Y, Ikuta M, Kitahara T, Furuichi T, Hirai H, et al. Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss. Aging Cell. 2025. doi:10.1111/acel.70331.
BibTeX
@article{masayuki2025Senesc,
title = {Senescent Cells Involved in Deterioration of Bone Microstructure by High‐Frequency Parathyroid Hormone 1–34 Administration and Bone Loss},
author = {Masayuki Bun and Yuichiro Ukon and Masato Ikuta and Takayuki Kitahara and Takuya Furuichi and Hiromasa Hirai and Daisuke Tateiwa and Yuya Kanie and Masayuki Furuya and Takahito Fujimori and Satoru Otsuru and Seiji Okada and Takashi Kaito},
journal = {Aging Cell},
year = {2025},
doi = {10.1111/acel.70331},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Nature Medicine 2017
Preprint · OA
Targeting cellular senescence prevents age-related bone loss in mice
Endocrinology and Metabolism Clinics of North America 2005
Citation only
Pathophysiology of Age-Related Bone Loss and Osteoporosis
Elsevier eBooks 2008
Citation only
Age-Related Bone Loss and Osteoporosis
Elsevier eBooks 2020
Citation only
Age-related bone loss and osteoporosis
Scientific Reports 2025
Open access · CC-BY
The adverse effects of chemotherapy on bone mass are not prevented by senolytics
Current Osteoporosis Reports 2019
Citation only